# Senti Biosciences Holdings, Inc. SNTI

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001854270


# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $51.2M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data, degenerate in...<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Apr 29, 2026<br>194 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $0.16<br>2026-11-06; market equity $5.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 27, 2026*

Unless the context otherwise requires, for purposes of this section, the terms "we," "us," "our," "our Company," "the Company" or "Senti" refer to Senti Biosciences, Inc. and its subsidiaries. We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 17.7** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (24.1%) | (6.6%) | | 17.7 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 78.7** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (30.52) | (0.37) | | 80.6 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 1.67x | 2.94x | | 76.9 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 96.4** | | | | | | |
| Revenue growth, three-year compound | (81.2%) | 10.0% | | 98.8 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (34.3%) | 2.2% | | 94.0 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *prior share count is 34 days earlier* | | | | | | |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 2.0 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (84.6%) | (2.1%) | 4 |
| Distance from 52-week high | (93.3%) | (30.4%) | 4 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (875.7%) | (1.0%) | 2 |
| Book value to price | (0.68) | 0.29 | 2 |
| Sales to price | 0.00 | 0.30 | 5 |
| Composite equity issuance, five years | not computable | 20.8% | |
| Relative strength against the sector, log excess return | (2.04) | (0.19) | 4 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $6.5M |
| Operating cash flow, four quarters | -$38.1M |
| Months of runway | 2.0 |
| Days since last periodic filing | 87 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $68,601 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$61.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$43.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 3 | assets | us-gaap:Assets | $51.2M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 4 | assets | us-gaap:Assets | $97.8M | 2024-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 5 | current assets | us-gaap:AssetsCurrent | $23.3M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $14.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$358.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$68.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 9 | book equity | us-gaap:StockholdersEquity | $5.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 10 | liabilities | us-gaap:Liabilities | $45.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $22,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2024-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.0M | 2023-12-31 | 2025-03-20 | 10-K | 25-000042 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.3M | 2022-12-31 | 2024-03-21 | 10-K | 24-000029 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $196,000 | 2025-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$41.4M | 2024-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $26,000 | 2024-12-31 | 2026-03-27 | 10-K | 26-021580 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$52.4M | 2023-12-31 | 2025-03-20 | 10-K | 25-000042 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $12.0M | 2023-12-31 | 2025-03-20 | 10-K | 25-000042 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$34.9M | 2022-12-31 | 2024-03-21 | 10-K | 24-000029 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $41.4M | 2022-12-31 | 2024-03-21 | 10-K | 24-000029 |
| 22 | assets | us-gaap:Assets | $119.5M | 2023-12-31 | 2025-03-20 | 10-K | 25-000042 |
| 23 | assets | us-gaap:Assets | $180.8M | 2022-12-31 | 2024-03-21 | 10-K | 24-000029 |
| 24 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 31,144,754 | 2026-04-22 | 2026-04-29 | 10-K/A | 26-028429 |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 31,144,497 | 2026-03-19 | 2026-03-27 | 10-K | 26-021580 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.